Updates matching "Cancer Research Funding"

Monica M. Bertagnolli, MD, will serve as the National Cancer Institute (NCI)’s new director, a role critical to ensuring ongoing innovation in oncology.

Ending the Sale of Flavored Tobacco is Critical to Protect Youth and Reduce Tobacco Use

Today the U.S. Senate Appropriations Committee released its FY 2023 spending bill that includes a $2 billion funding increase for the National Institutes of Health (NIH), including a $291 million funding boost for the National Cancer Institute (NCI).

An article released today in JAMA Network Open details the potential benefits of using technology to increase patient participation in cancer clinical trials. In a survey of nearly 1,200 recent cancer patients and survivors, more than 80% said they would be willing to use remote technologies and tools in a trial.

The House Appropriations Committee will vote today to approve its FY 2023 spending bill including a $2.5 billion funding increase for the National Institutes of Health (NIH), a $466 million funding boost for the National Cancer Institute (NCI) and $2.75 billion for the Advanced Research Projects Agency on Health (ARPA-H).

Dr. Karen E. Knudsen, the Chief Executive Officer of the American Cancer Society and American Cancer Society Cancer Action Network (ACS CAN), will testify before the House Appropriations Subcommittee on Labor, Health, and Human Services and Education, and related agencies today in support of increased federal funding for the National Institutes of Health (NIH), National Cancer Institute (NCI) and the Centers for the Disease Control and Prevention (CDC).

Eighty-seven organizations representing patients with chronic and acute health conditions, sent a letter to Congress today urging them to improve the diversity of enrollment in clinical trials as part of this year’s Prescription Drug User Fee Act (PDUFA) reauthorization.

National Cancer Institute (NCI) director, Dr. Ned Sharpless, has announced he intends to leave his post at NCI at the end of April. Dr. Sharpless has led the Institute for five years during which time he proved to be a tireless advocate for increased investment in cancer research.